Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $11.3 million.

  • Arrowhead Pharmaceuticals' Free Cash Flow rose 10736.92% to $11.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $322.0 million, marking a year-over-year increase of 15632.72%. This contributed to the annual value of $156.9 million for FY2025, which is 12595.51% up from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported Free Cash Flow of $11.3 million as of Q4 2025, which was up 10736.92% from $13.0 million recorded in Q3 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Free Cash Flow ranged from a high of $454.8 million in Q1 2025 and a low of -$186.5 million during Q4 2023
  • Its 5-year average for Free Cash Flow is -$38.2 million, with a median of -$72.9 million in 2022.
  • In the last 5 years, Arrowhead Pharmaceuticals' Free Cash Flow soared by 92293.71% in 2021 and then tumbled by 21478.22% in 2022.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Free Cash Flow (Quarter) stood at -$67.1 million in 2021, then plummeted by 70.57% to -$114.4 million in 2022, then crashed by 62.98% to -$186.5 million in 2023, then rose by 17.54% to -$153.8 million in 2024, then surged by 107.37% to $11.3 million in 2025.
  • Its Free Cash Flow stands at $11.3 million for Q4 2025, versus $13.0 million for Q3 2025 and -$157.1 million for Q2 2025.